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Abstract
Many of the minor complaints of old age may have a common etiology and are grouped together here under
the term ‘the lesser ailments of aging’ (LAA). This essay proposes that they are due in large part to an age-linked
reduced microcirculation. Capillary density (CD) in the tissues is determined by levels of angiogenic growth factors
(AGFs). Over 47 studies have reported a reduced CD and/or waning AGFs throughout the bodies of aging animals
and people. More convincing than such a generalization are the 80 sets of data comparing these two parameters in
adult vs. the aged. These data have led to a hypothesis whose corollary proposes a specific treatment for the LAA.
While genetically controlled, the waning levels of AGFs theoretically could be countered by pro-angiogenesis
therapy and thus might ease the LAA or delay their onset. Therapies mentioned here include recombinant AGFs
and inhibitors of type 5 phosphodiesterases, such a tadalafil/Cialis. Finally, Alzheimer’s disease (AD) is generally
an illness of the elderly and may have a single or multiple causes. However, its clinical course may be influenced
secondarily by conditions affecting the LAA. Therefore, any effective treatment of them may influence favorably the
clinical course of AD.

Introduction
Diminished blood flow to the brain and other organ systems may
result from an impaired microcirculation due to pathological changes
in the capillaries or reduced numbers of capillaries. The former are
reflected in twisting, kinking, and looping of capillaries in the cerebral
cortex [1-3]. Whether these changes progress to reduced capillary
numbers by cellular atrophy has not been demonstrated and is not
considered further here. However, the widespread reduced capillary
density (CD) found in aged animals and people has been correlated
with diminished levels of angiogenic growth factors (AGFs) [4-6].
The association between CD and AGFs during old age is the focus
of this essay, which advances two ideas. 1) The reduced CD of old age
may be the main, primary cause of many symptoms and signs of the
elderly, i.e., the ‘lesser ailments of aging’. 2) A reduced CD may also be
an underlying, secondary condition for other diseases associated with
aging and may facilitate the action of factors postulated to cause them -e.g. amyloid plaques, neurofibrillary tangles, etc. of Alzheimer’s disease
(AD) or Lewy bodies, proposed malfunctioning mitochondria, etc. of
Parkinson’s disease (PD).

The Lesser Ailments of Aging
People die from accidents and major diseases. The rest live on
through old age with generally two sorts of complaints: chronic
afflictions and/or lesser ailments. The former involve arthritis, diabetes,
atrial fibrillation, Parkinson’s disease, or other distressing illnesses and
are not a concern here. The latter, the lesser ailments, include minor
symptoms, such as general muscle weakness, cold intolerance, memory
lapses for names or words, and momentarily dozing, especially during
the evening hours [6]. Also included are physical signs, such as wrinkled
skin on the face and dorsum of the hands and the slow healing of
bruises and abrasions. These symptoms and signs may share a common
etiology which is the reduced capillary density that develops throughout
the body during old age.
As discussed elsewhere, a reduced CD in aged persons and animals
has been described in over 40 reports and noted in many organ systems
-- i.e., brain, muscle, skin, larynx, lung, colon, kidney and vasa vasorum
[5,6]. Capillaries are formed and maintained by angiogenic growth
factors (AGFs), whose levels are genetically programmed during early
development and throughout life. A decline in AGFs in the aged has
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been described in seven other reports and noted in five organ systems
-- i.e., the brain, muscles, kidney, mononuclear cells, and vein wall
[5,6]. Among the AGFs are vascular endothelial growth factor (VEGF),
fibroblast growth factors (FGFs), and other such factors. For this essay,
the important aspect of these AGFs is that during old age their levels
decline, resulting in a reduced capillary density in the tissues. Thus, the
lesser ailments reflect a deficiency condition of AGFs, much like the
reduced testosterone levels in elderly males.
In the literature little mention has been made that the decline in
the levels of AGFs in the elderly is genetically programmed. Whether
amyloid plaques or other factors can also influence capillary density is
unclear.

The Importance of Data
In theory from the above analysis, the lesser ailments should be
relieved or delayed by pro-angiogenic therapy -- e.g., recombinant forms
of VEGF, FGF, or other angiogenic agents. This is a novel idea which
must be introduced with persuasive data to be seriously considered by
students of aging.
Merely listing a large number of papers sharing a common effect
does not convey so convincingly their importance as does showing the
relevant data. Age-linked changes are presented here in the form of
‘data pairs’ -- i.e., values of CD or AGFs in adult animals or people vs.
those in their aged counterparts. For example, Amenta et al. measured
the capillary density in three areas of the brain of rats age 12 months vs.
18 months old and reported reduction of the CD as follows -- frontal
cortex: 122 vs. 71, occipital cortex: 130 vs. 82 and hippocampus: 113 vs.
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58 [7]. Similarly, Haidet et al. compared the CD in three muscle areas
of beagle dogs ages 2-3 years vs. 10-14 years and found the following
-- gastrocnemius: 886 vs. 718, semitendinosus: 895 vs. 658, and triceps:
959 vs. 805 [8]. These six sets of data are more persuasive than a
generalization that papers by Amenta and Haidet show an age-linked
reduce CD.
As noted above, an examination of the research literature on aging
and angiogenesis has disclosed 47 studies concerning CD and levels of
AGFs. They have provided 80 data pairs showing age-linked reduced CD
and declining AG. These paired figures have been presented elsewhere
in tables and are the basis for a hypothesis that the reduced capillary
numbers in the elderly account in part for their lesser ailments [4-6].

Cause and Effect
The mere temporal association of two events -- here, a reduced
CD throughout the body with aging and the age-linked development
of LAA -- does not establish by itself cause and effect. Definitive proof
would be showing that pro-angiogenesis therapy relieved or delayed
onset of the lesser ailments. This proof has yet to be established.
However, many experimental studies employing recombinant forms
of AGFs support the hypothesis, as discussed in detail elsewhere [6,9].
For example, injection of VEGF or FGF into the normal cerebral cortex
or ventricle of animals elicits cortical angiogenesis [10,11]. Occlusion
of the femoral artery in an animal’s hind limb evokes ischemia there,
which is relieved by local injections of AGFs [12]. Pro-angiogenesis
treatment produced suggestive clinical improvement in subjects with
intermittent claudication or cardiac insufficiency [13,14].

five reports with 11 data pairs. Table 1 lists the CD in AD patients
compared to values in an adult group or an aged group. Since all AD
subjects here were elderly, a reduced CD found in them might merely
reflect their age and not a specific effect on the AD aspect of their state of
health. However, four data pairs suggest a slightly greater reduced CD
in AD subjects compared with similarly aged persons -- e.g., reports #1
(entorhinal cortex), #3, and #4.
Other studies on AD patients suggest an impaired cerebral
microcirculation. 1) Farkas et al. [15]
postulated
that
capillary
dysfunction occurs in both Alzheimer’s diseases and Parkinson’s disease,
based on finding a 2-fold increase in basement membrane deposits in these
two conditions. 2) Hunter et al. found elevated numbers of degenerated
string capillaries in AD brains but no overall reduced CD. However,
the “total brain mass, determined at autopsy, was significantly less in
AD compared to ND [non-demented] control groups” [16]. Cortical
shrinkage may mask any reduced cerebral capillary counts, as discussed
elsewhere [4]. 3) Sweat and Jicha reported that “capillary length-density
was greater in AD...in the frontal neocortex” but postulated atrophy of the
brain “as responsible” [17]. 4) Miners et al. reported a reduced CD and
diminished levels of VEGF in cases of dementia with Lewy bodies [18]. 5)
Parenthetically, Mateo et al. reported lower serum VEGF levels in subjects
with Alzheimer’s disease [19].

The natural course of AGFs during animal/human life offers
inferential support to the angiogenesis hypothesis. During early life,
the rising levels of AGFs and the maturing microcirculation determine
the development of various organ systems and account for the healthy
functioning of the body. During old age, the waning levels of AGFs and
the declining CD parallel the falling organ function and may logically
account for the emerging symptoms and signs of aging -- notably the
general muscle weakness of the lesser ailments.

Some gerontologists contend that AD involves a reduced cerebral
microcirculation and have considered pro-angiogenesis therapy to aid
this condition. For example, in 2004 Ward and LaManna wrote that “we
now know angiogenesis is involved in Alzheimer’s disease” and several
other neurological disorders [20]. They suggested that “controlling
angiogenesis may also provide novel therapeutic approaches for
treatment of these disorders.” In 2011, Wang et al. also wrote that “that
VEGF should be pursued as a novel therapeutic agent for treatment of
AD” [21]. These latter authors had found that therapeutic angiogenesis
ameliorated the memory impairment in APP transgenic mouse model
of Alzheimer’s disease. And in 2015, Baloyannis considered that
“protection of the brain capillaries at the initial stages of the disease”
might reduce “the pathological alterations” in AD [22].

Alzheimer’s Disease

Pro-Angiogenesis Therapy

Alzheimer’s disease is a dreaded development during aging in
many persons. A reduced CD in subjects with AD is documented in

Three therapeutic approaches for easing the lesser ailments warrant
consideration.

Authors

Adults

Aged

AD

Mean capillary density mm/mm3

av. 38year (5)

av. 74 year (5)

av. 78 year (5)
111

Entorhinal cortex

148

124

Overall of 6 zones

124

102

101

Av. Capillary density mm/mm3

12-54 year (8)

67-95 year (8)

63-92 year (10)

Visual cortex, lamina 1

141

99

97

Visual cortex, av. of 6 laminae

251

212

206

% capil, surface area of total cortical field area

49 year (1)

av. 79 year (3)

av. 80 year (7)

Cortical areas

26.32%

18.95%

16.50%

Capillary density in test grid method

73 ± 4 year (6)

79 ± 12 year (8)

Frontal cortex

c. 28

c.21

Parietal cortex

c. 28

c.20

Vascular density index

23-90 year (6)

76-92 year (16)

Prefrontal cortex

94.6

75.4

Basal forebrain

86.8

42.7

Hippocampus

82.3

50.2

Motor sensory cortex

94.3

83.1

Note: c=value extrapolated from figure listed; other values listed here are cited in text; ( )=number of subjects
Table 1: Cerebral capillary density in adults/aged and AD subject.
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1) Employing recombinant angiogenic growth factors (VEGF, FGF
or others) has been discussed at length in previous papers [4-6].
Their weaknesses for clinical use include being destroyed in the
intestinal tract when administered orally and a short half- life
in the circulation. These problems could be overcome in part
by nasal administration in snuff or nose drops, as suggested
and explained elsewhere [4,23].

7. Amenta F, Cavallotti D, Del Valle M, Mancini M, Naves FJ, et al. (1995)
Age-related changes in brain microanatomy: Sensitivity to treatment with the
dehydropyridine calcium channel blocker darodipine (PY 108-068). Brain Res
Bull 36: 453-460.

2) Physical exercise evokes production of VEGF by striated muscles
[5]. The released endogenous factor may enhance muscle
function locally with new capillaries but also might reach the
brain via the blood, increase the cerebral microcirculation, and
improve memory and cognition. Exercise has been popularly
recommended to improve mental sharpness [24].

10. Rosenstein JM, Mani N, Silverman WF, Krum JM (1998) Patterns of brain
angiogenesis after vascular endothelial growth factor administration in vitro and
in vivo. Proc Nat Acad Sci USA 95: 7086-7091.

3) A recent option is testing a long acting inhibitor of the type 5
phosphodiesterase (PDE5), such as tadalafil/Cialis.
Besides angiogenic growth factors (VEGF, FGF, etc.), several
newly developed drugs in wide clinical use have been shown to elicit
angiogenesis. They include sildenafil (Viagra) and tadalafil (Cialis),
which are prescribed to treat various medical conditions, including
erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and
pulmonary arterial hypertension (PAH) [25]. The drugs’ intended
effect in patients is to produce vasodilation, but in animal studies both
have been shown also to induce capillary formation in ischemic tissues/
organs [26-31]. These drugs regulate a key intermediate in metabolic
pathways leading to capillary formation, as outlined elsewhere
[32]. They are effective when administered orally. For promoting
angiogenesis, Cialis would be the superior PDE5 inhibitor because it
has a longer biological half-life -- 17.5 h for Cialis vs. 4 h. for Viagra.

Conclusion
This short commentary has been a defense of the angiogenesis
hypothesis of aging and the grouping together of the lesser ailments
of aging (LAA). More difficult to support or prove is the idea that a
reduced CD may facilitate the mechanisms or agents which have been
proposed to cause AD and PD. It seems logical to believe that brain
nutritionally impaired by a reduced cerebral microcirculation may be
more vulnerable to specific pathological insults -- e.g., amyloid plaques,
Lewy bodies, etc. But the reciprocal consideration suggests that a wellnourished brain may slow the onset of the genetically fated cognitive
decline. Thus pro-angiogenesis treatment seems a tenable approach for
dealing with the LAA and indirectly with AD and PD.
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